Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker QGEN · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Sep 24, 2026 | QIAstat-Dx BCID GN Plus AMR Panel | QGEN Qiagen GmbH | Device clearance (510(k)) Traditional | K262168 ↗ |
| Aug 6, 2026 | QIAstat-Dx BCID GPF Plus AMR Panel | QGEN Qiagen GmbH | Device clearance (510(k)) Traditional | K254194 ↗ |
| May 6, 2026 | QIAGEN therascreen® FGFR RGQ RT-PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Real-Time Process | P180043 ↗ |
| Mar 9, 2026 | QIAstat-Dx Gastrointestinal Panel 2; QIAstat-Dx GI Panel 2… | QGEN Qiagen GmbH | Device clearance (510(k)) Traditional | K254032 ↗ |
| Nov 21, 2025 | QuantiFERON-TB Gold Plus Test TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS | QGEN Qiagen | Device approval (PMA), supplement Real-Time Process | P010033 ↗ |
| Oct 22, 2025 | therascreen® PIK3CA RGQ PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Normal 180 Day Track | P190001 ↗ |
| Oct 22, 2025 | QIAstat-Dx Gastrointestinal Panel 2; QIAstat-Dx GI Panel 2… | QGEN Qiagen GmbH | Device clearance (510(k)) Traditional | K252329 ↗ |
| Oct 3, 2025 | QIAGEN therascreen® FGFR RGQ RT-PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Normal 180 Day Track | P180043 ↗ |
| Aug 27, 2025 | QIAstat-Dx Respiratory Panel Plus; QIAstat-Dx Respiratory P… | QGEN Qiagen GmbH | Device clearance (510(k)) Traditional | K250080 ↗ |
| Feb 28, 2025 | QIAstat-Dx GI Panel 2 Mini B | QGEN Qiagen GmbH | Device clearance (510(k)) Special | K250324 ↗ |
| Jan 16, 2025 | therascreen® KRAS RGQ PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Normal 180 Day Track | P110027 ↗ |
| Jan 8, 2025 | QIAstat-Dx GI Panel 2 Mini B&V | QGEN Qiagen GmbH | Device clearance (510(k)) Special | K243813 ↗ |
| Dec 6, 2024 | therascreen FGFR RGQ PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P180043 ↗ |
| Oct 29, 2024 | QIAstat-Dx Meningitis/Encephalitis (ME) Panel | QGEN Qiagen GmbH | Device clearance (510(k)) Traditional | K242256 ↗ |
| Oct 25, 2024 | QIAstat-Dx Respiratory Panel Mini | QGEN Qiagen GmbH | Device clearance (510(k)) Special | K242353 ↗ |
| Jun 21, 2024 | therascreen® KRAS RGQ PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Normal 180 Day Track | P110027 ↗ |
| May 31, 2024 | QIAstat-Dx Gastrointestinal Panel 2 | QGEN Qiagen GmbH | Device clearance (510(k)) Traditional | K220062 ↗ |
| May 10, 2024 | QIAstat-Dx® Respiratory Panel Plus | QGEN Qiagen GmbH | Device clearance (510(k)) Traditional | K233100 ↗ |
| Oct 6, 2023 | QIAGEN therascreen® KRAS RGQ PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Special (Immediate Track) | P110027 ↗ |
| Jun 29, 2023 | therascreen PDGFRA RGQ PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA) | P210002 ↗ |
| Jan 24, 2023 | QUANTIFERON®-TB Gold Plus Test TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS | QGEN Qiagen | Device approval (PMA), supplement Real-Time Process | P010033 ↗ |
| Dec 12, 2022 | therascreen KRAS RGQ PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Normal 180 Day Track | P110027 ↗ |
| Jun 17, 2022 | therascreen KRAS RGQ PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Special (Immediate Track) | P110027 ↗ |
| Dec 13, 2021 | QuantiFERON®-TB Gold, QuantiFERON®-TB Gold Plus TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS | QGEN Qiagen | Device approval (PMA), supplement Normal 180 Day Track | P010033 ↗ |
| Nov 16, 2021 | therascreen FGFR RGQ RT-PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Real-Time Process | P180043 ↗ |
| Jul 7, 2021 | therascreen EGFR RGQ PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Real-Time Process | P120022 ↗ |
| May 28, 2021 | therascreen KRAS RGQ PCR KIT Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Panel Track | P110027 ↗ |
| Aug 18, 2020 | therascreen FGFR RGQ RT-PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Normal 180 Day Track | P180043 ↗ |
| Apr 15, 2020 | therascreen BRAF V600E RGQ PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA) | P190026 ↗ |
| Oct 11, 2019 | PartoSure Test Placental alpha microglobulin-1 immunoassay | QGEN Qiagen, Inc. | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P160052 ↗ |
| Sep 26, 2019 | therascreen EGFR RGQ PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Special (Immediate Track) | P120022 ↗ |
| May 24, 2019 | therascreen PIK3CA RGQ PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA) | P190004 ↗ |
| May 24, 2019 | therascreen PIK3CA RGQ PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA) | P190001 ↗ |
| May 18, 2019 | QIAstat-Dx Respiratory Panel | QGEN Qiagen GmbH | Device clearance (510(k)) Traditional | K183597 ↗ |
| Apr 29, 2019 | Quantiferon - TB Gold Plus Test TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS | QGEN Qiagen | Device approval (PMA), supplement Real-Time Process | P010033 ↗ |
| Apr 12, 2019 | therascreen FGFR RGQ RT-PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA) | P180043 ↗ |
| Oct 30, 2018 | QuantiFERON-TB Gold Test / QuantiFERON TB Gold Plus Test TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS | QGEN Qiagen | Device approval (PMA), supplement Real-Time Process | P010033 ↗ |
| Sep 27, 2018 | therascreen EGFR RGQ PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Normal 180 Day Track | P120022 ↗ |
| Aug 24, 2018 | QuantiFeron TB Gold and QuantiFeron TB Gold Plus TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS | QGEN Qiagen | Device approval (PMA), supplement 135 Review Track For 30-Day Notice | P010033 ↗ |
| Apr 11, 2018 | PartoSure test Placental alpha microglobulin-1 immunoassay | QGEN Qiagen, Inc. | Device approval (PMA) | P160052 ↗ |
| Mar 13, 2018 | artus CMV RGQ MDx Kit and artus CMV QS-RGQ MDx Kit Cytomegalovirus (cmv) dna quantitative assay | QGEN Qiagen, Inc. | Device approval (PMA), supplement 135 Review Track For 30-Day Notice | P130027 ↗ |
| Jan 12, 2018 | Therascreen EGFR RGQ PCR Kit Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Normal 180 Day Track | P120022 ↗ |
| Jan 12, 2018 | ipsogen JAK2 RGQ PCR Kit | QGEN Qiagen, Inc. | Device clearance (510(k)) Traditional | K172287 ↗ |
| Nov 15, 2017 | Artus CMV RGQ and QS-RGQ MDx Kit Cytomegalovirus (cmv) dna quantitative assay | QGEN Qiagen, Inc. | Device approval (PMA), supplement Normal 180 Day Track | P130027 ↗ |
| Jun 7, 2017 | QUANTTFERON-TB GOLD Plus TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS | QGEN Qiagen | Device approval (PMA), supplement Normal 180 Day Track | P010033 ↗ |
| Jun 2, 2017 | ARTUS CMV RGQ MDX KIT Cytomegalovirus (cmv) dna quantitative assay | QGEN Qiagen, Inc. | Device approval (PMA), supplement Normal 180 Day Track | P130027 ↗ |
| May 19, 2017 | THERASCREEN EGFR RGQ PCR KIT Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Normal 180 Day Track | P120022 ↗ |
| Mar 27, 2017 | ipsogen JAK2 RGQ PCR Kit | QGEN Qiagen, Inc. | Device clearance (510(k)) De Novo | DEN160028 ↗ |
| Nov 9, 2015 | THERASCREEN EGFR RGQ PCR KIT Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P120022 ↗ |
| Nov 9, 2015 | THERASCREEN KRAS RGQ PCR KIT Somatic gene mutation detection system | QGEN Qiagen GmbH | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P110027 ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:36 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates